Recombinant Human CNTN1 protein(Met1-Ser993), His-tagged

• Cat.No.: CNTN1-670H
• Product Overview: Recombinant Human CNTN1 (NP_001834.2)(Met1-Ser993) was expressed in HEK293 with the fused C-terminal polyhistidine tag.

Specification

• Species: Human
• Source: HEK293
• Tag: His
• Protein Length: Met1-Ser993
• Form: Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.
• Molecular Mass: The secreted recombinant human CNTN1 comprises 984 amino acids after removal of the signal peptide and has a predicted molecular mass of 110 kDa. In SDS-PAGE under reducing conditions, the apparent molecular mass of rhCNTN1 is approximately 125 kDa due to glycosylation.
• Endotoxin: < 1.0 EU per μg of the protein as determined by the LAL method.
• Purity: > 95 % as determined by SDS-PAGE
• Storage: Samples are stable for up to twelve months from date of receipt at -20°C to -80°C. Store it under sterile conditions at -20°C to -80°C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
• Reconstitution: It is recommended that sterile water be added to the vial to prepare a stock solution of 0.2 ug/ul. Centrifuge the vial at 4°C before opening to recover the entire contents.

Gene Information

• Gene Name: CNTN1 contactin 1 [ Homo sapiens ]
• Official Symbol: CNTN1
• Synonyms: CNTN1; contactin 1; contactin-1; F3; glycoprotein gP135; GP135; neural cell surface protein F3
• Gene ID: 1272
• mRNA Refseq: NM_001256063
• Protein Refseq: NP_001242992
• MIM: 600016
• UniProt ID: Q12860

Case Study

Case 1: Shi K, et al. Int J Clin Exp Pathol. 2015

Contactin 1 (CNTN1) is part of the immunoglobulin family and plays a key role in nervous system development. It’s been found to aid cancer spread when present in high levels. Surprisingly, in thyroid cancer, CNTN1 is newly linked to the RET/PTC3 gene and shows higher protein levels, correlating with more advanced tumor stages and sizes. By reducing CNTN1, tumor growth and invasiveness drop, along with a decrease in cyclin D1. Thus, CNTN1 could be a valuable marker and target for thyroid cancer diagnosis and treatment.

Fig1. The protein expression of CNTN1 in CNTN1 interfered thyroid cancer cell lines.

Fig2. Thyroid cancer cell lines B-CPAP and BHT101 were transfected with 100 nM CNTN1 RNAi or control RNA.

Case 2: Le Quintrec M, et al. Kidney Int. 2021

Primary membranous nephropathy (MN) is when the body mistakenly attacks kidney proteins. For most cases, the culprit is the phospholipase A2 receptor 1 (PLA2R1). But in 20%, we don’t know what the target is. Sometimes, MN is linked with a nerve disorder called chronic inflammatory demyelinating polyneuropathy. To find a new target, we studied kidney biopsies from patients with MN and this nerve disorder, all having antibodies against contactin 1. Tests showed contactin 1 is in kidney tissues where these antibodies bind. This wasn't seen in patients with other forms of MN or healthy samples. This suggests contactin 1 might be a new key player in these linked conditions.

Fig1. Contactin-1 (CNTN1) is expressed in human (H) glomeruli detected by immunoblotting.

Fig2. The subclass of eluted IgG was determined by enzyme-linked immunosorbent assay against CNTN1.

Application

Recombinant CNTN1 protein, a lab-created version of contactin-1, is like a new tool for doctors and scientists. In the nervous system, CNTN1 helps neurons grow and mend. By tinkering with recombinant CNTN1, researchers aim to decode nerve damage and develop therapies for neurodegenerative disorders. It’s much like handing researchers a fresh set of instruments to figure out the intricate web of how nerves grow and heal. Aside from nerve studies, recombinant CNTN1 is making waves in cancer research. Since CNTN1 is linked to how cancer cells spread, it might pave the way for new cancer treatments. By cracking the code on these interactions, therapies could become more precise, giving hope to many battling cancer. In short, recombinant CNTN1 isn’t just a scientific breakthrough—it’s a beacon of hope in both brain research and cancer therapy.

Fig1. Graphic illustration of the currently known mechanisms underlying CNTN1-induced migration and invasion of cancer cells. (Yan Gu, 2020)